---
title: "Cue Biopharma (CUE) surges nearly 80% intraday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284906416.md"
description: "Cue Biopharma（CUE.US）现价 $26.500，当日 +79.78%，盘中涨势显著，市值 0.92 亿。公司专注于免疫药物研发，股价因盘前及盘后持续上涨引发关注。近日媒体报道公司盘前大涨超过 65%，市场聚焦其潜在临床进展和资金流入，催化原因未有明确公告。"
datetime: "2026-05-01T13:56:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284906416.md)
  - [en](https://longbridge.com/en/news/284906416.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284906416.md)
---

# Cue Biopharma (CUE) surges nearly 80% intraday

Cue Biopharma (CUE.US) is trading at $26.500, up **+79.78%** intraday with sharp gains. Market cap stands at $92 million.

The company focuses on immunotherapy drug development. Shares gained significant momentum pre-market and after-hours, driven by investor attention to possible clinical progress and capital inflows. No specific catalyst has been officially announced.

### Related Stocks

- [CUE.US](https://longbridge.com/en/quote/CUE.US.md)

## Related News & Research

- [Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments | CUE Stock News](https://longbridge.com/en/news/286460513.md)
- [Cue Biopharma Q1 net loss narrows on lower R&D costs](https://longbridge.com/en/news/286463248.md)
- [Cue Biopharma Announces $30 Million Private Placement | CUE Stock News](https://longbridge.com/en/news/284830191.md)
- [Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?](https://longbridge.com/en/news/286727957.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)